The stock price of Kymera Therapeutics Inc (NASDAQ: KYMR) has dropped by -5.28 compared to previous close of 35.21. Despite this, the company has seen a fall of -5.04% in its stock price over the last five trading days. GlobeNewsWire reported 2024-02-28 that WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
Is It Worth Investing in Kymera Therapeutics Inc (NASDAQ: KYMR) Right Now?
KYMR has 36-month beta value of 2.30. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KYMR is 54.16M, and currently, short sellers hold a 17.91% ratio of that float. The average trading volume of KYMR on April 26, 2024 was 652.76K shares.
KYMR’s Market Performance
The stock of Kymera Therapeutics Inc (KYMR) has seen a -5.04% decrease in the past week, with a -15.55% drop in the past month, and a 4.74% gain in the past quarter. The volatility ratio for the week is 5.64%, and the volatility levels for the past 30 days are at 4.87% for KYMR. The simple moving average for the last 20 days is -8.09% for KYMR’s stock, with a simple moving average of 30.60% for the last 200 days.
Analysts’ Opinion of KYMR
Many brokerage firms have already submitted their reports for KYMR stocks, with Oppenheimer repeating the rating for KYMR by listing it as a “Outperform.” The predicted price for KYMR in the upcoming period, according to Oppenheimer is $53 based on the research report published on April 22, 2024 of the current year 2024.
KYMR Trading at -14.40% from the 50-Day Moving Average
After a stumble in the market that brought KYMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.40% of loss for the given period.
Volatility was left at 4.87%, however, over the last 30 days, the volatility rate increased by 5.64%, as shares sank -16.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.80% lower at present.
During the last 5 trading sessions, KYMR fell by -5.04%, which changed the moving average for the period of 200-days by +48.02% in comparison to the 20-day moving average, which settled at $35.95. In addition, Kymera Therapeutics Inc saw 30.99% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KYMR starting from Booth Bruce, who sale 71,764 shares at the price of $40.46 back on Mar 15 ’24. After this action, Booth Bruce now owns 806,697 shares of Kymera Therapeutics Inc, valued at $2,903,336 using the latest closing price.
Booth Bruce, the Director of Kymera Therapeutics Inc, sale 55,779 shares at $39.98 during a trade that took place back on Mar 14 ’24, which means that Booth Bruce is holding 819,151 shares at $2,229,927 based on the most recent closing price.
Stock Fundamentals for KYMR
Current profitability levels for the company are sitting at:
- -2.11 for the present operating margin
- 0.95 for the gross margin
The net margin for Kymera Therapeutics Inc stands at -1.81. The total capital return value is set at -0.34. Equity return is now at value -33.21, with -24.93 for asset returns.
Based on Kymera Therapeutics Inc (KYMR), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.21. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -1452.02.
Currently, EBITDA for the company is -143.2 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 25.61. The receivables turnover for the company is 4.19for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.73.
Conclusion
To put it simply, Kymera Therapeutics Inc (KYMR) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
